The stock last traded at $35.01 which is significantly higher than $29.14, the 50 day moving average and significantly above the 200 day moving average of $29.04. The 50 day moving average was up $5.87 whereas the 200 day average was up by +20.55%. Cellectis S.A. – American Depos shares had a trading volume of 213K in the last trading session. Trading volume was up 19.57% over the stocks average daily volume.
Investors are feeling more bullish on shares of the company of late if you consider the fall in short interest. The firm recorded a fall in short interest of -24.25% as of October 13, 2017 from the last reporting period. Short interest decreased from 680,314 to 515,344 over that period. The days to cover decreased to 6.0 and the percentage of shorted shares was 0.01% on October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (CLLS). As of the end of the quarter Vident Investment Advisory, LLC had sold 1,013 shares trimming its position 2.0%. The value of the company’s investment in Cellectis S.A. – American Depos increased from $1,224,000 to $1,291,000 a change of $67,000 since the last quarter. As of quarter end Venbio Select Advisor LLC had disposed of a total of 11,407 shares trimming its stake by 11.7%. The value in dollars went from $2,330,000 to $2,212,000 a change of 5.1% quarter over quarter.
Next Financial Group, Inc reduced its stake by selling 100 shares a decrease of 25.0% in the quarter. Next Financial Group, Inc currently owns 300 shares worth $8,000,000. The total value of its holdings increased 79,900.0%. As of quarter end Cutler Group LP had sold a total of 600 shares trimming its holdings by 73.1%. The value of the total investment in Cellectis S.A. – American Depos went from $21,000 to $6,000 decreasing 71.4% quarter to quarter.
As of the last earnings report the EPS was $-2.30 and is projected to be $-2.39 for the current year with 35,862,000 shares outstanding. Next quarter’s EPS is forecasted to be $-0.41 and the next full year EPS is anticipated to be $-2.20.
Cellectis S.A., a gene-editing company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART38 for T-cell ALL and MM; and UCART22 for ALL. It has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; and The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various types of liquid tumors. Cellectis S.A. was founded in 1999 and is based in Paris, France..